✦ LIBER ✦

Interferon alpha-2c therapy of patients with chronic myelogenous leukemia: long-term results of a multicenter phase-II study

✍ Scribed by J. Thaler; G. Gastl; T. Fluckinger; D. Niederwieser; H. Huber; H. Seewann; H. Sill; A. Lang; M. Falk; C. Duba; G. Utermann; T. Kühr; W. Aulitzky; C. Huber; Austrian Biological Response Modifier (BRM) Study Group*

Publisher: Springer
Year: 1996
Tongue: English
Weight: 228 KB
Volume: 72
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s002770050185

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II study alternating alpha-2a-in

A phase II study alternating alpha-2a-interferon and gamma-interferon therapy in patients with chronic myelogenous leukemia

✍ M. Talpaz; R. Kurzrock; H. Kantarjian; J. Rothberg; S. Saks; L. Evans; J. U. Gut 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 549 KB

Interferon alfa-2c in chronic myelogenou

Interferon alfa-2c in chronic myelogenous leukemia (CML): Hematologic, cytogenetic and molecular-genetic response of patients with chronic phase CML previously resistant to therapy with interferon gamma

✍ Herrmann, F. ;Jonas, D. ;Helfrich, S. G. ;Lindemann, A. ;Schleiermacher, E. ;Mer 📂 Article 📅 1990 🏛 Springer-Verlag ⚖ 849 KB

Multicenter prospective study of interfe

Multicenter prospective study of interferon-α versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia: a preliminary analysis

✍ Kazunori Ohnishi; Teruo Ino; Yuji Kishimoto; Noriko Usui; Chihiro Shimazaki; Shi 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 100 KB

Results of triple therapy with interfero

Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in early chronic phase

✍ Susan O'Brien; Francis Giles; Moshe Talpaz; Jorge Cortes; Mary Beth Rios; Jianqi 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB 👁 1 views

## Abstract ## BACKGROUND Before the discovery of imatinib mesylate, a Bcr‐Abl selective tyrosine kinase inhibitor, three agents, interferon‐alpha (IFN‐α), cytarabine (ara‐C), and homoharringtonine (HHT), had demonstrated activity against Philadelphia chromosome (Ph)‐positive chronic myelogenous l

Interferon α therapy for patients with e

Interferon α therapy for patients with essential thrombocythemia : Final results of a phase II study initiated in 1986

✍ Rashid Saba; Elias Jabbour; Francis Giles; Jorge Cortes; Moshe Talpaz; Susan O'B 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB 👁 1 views

Chronic myelogenous leukemia in nonlymph

Chronic myelogenous leukemia in nonlymphoid blastic phase : Analysis of the results of first salvage therapy with three different treatment approaches for 162 patients

✍ Stefano Sacchi; Hagop M. Kantarjian; Susan O'Brien; Jorge Cortes; Mary Beth Rios 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB 👁 2 views

## BACKGROUND. The prognoses of patients with chronic myelogenous leukemia in blastic phase (CML-BP) are extremely poor. Treatment of patients with nonlymphoid CML-BP is associated with very low response rates, a median survival of 2-3 months, and significant toxicities. The aim of this study was